Furthermore, functional assays demonstrated that PARP3 drives AML progression by stimulating proliferation and migration through the PI3K/AKT/mTOR axis, identifying it as a promising therapeutic target. This evidence concerns the gene AKT1 and acute myeloid leukemia.